Physician profile
Forrest Swan
NPI 1841284429
$837.32
in general payments reported to CMS, 2019-2025
21 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.01 · 2020: $37.99 · 2021: $11.92 · 2022: $133 · 2023: $163 · 2024: $71.22 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.02 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $91.70 | 2023 | |
| Incyte Corporation | $85.40 | 2025 | Jakafi, Zynyz, Niktimvo |
| Pharmacyclics LLC, An Abbvie Company | $83.47 | 2022 | |
| Daiichi Sankyo INC. | $80.33 | 2025 | Vanflyta, Injectafer, Datroway |
| Celgene Corporation | $44.24 | 2022-2023 | Pomalyst |
| Merck Sharp & Dohme LLC | $41.24 | 2019-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $32.78 | 2024 | |
| Janssen Biotech, INC. | $30.15 | 2023 | Tecvayli, Darzalex |
| Acrotech Biopharma INC. | $26.48 | 2025 | Beleodaq |
| Amgen INC. | $25.66 | 2019-2022 | |
| Avyxa Pharma, LLC | $24.65 | 2025 | |
| Abbvie INC. | $24.06 | 2024 | |
| Rigel Pharmaceuticals, INC. | $22.81 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Janssen Pharmaceuticals, INC | $19.08 | 2025 | Carvykti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $18.97 | 2025 | |
| Seagen INC. | $18.90 | 2022 | |
| Taiho Oncology, INC. | $17.10 | 2025 | |
| Kite Pharma, INC. | $13.85 | 2023 | Yescarta |
| Biocompatibles, INC. | $13.51 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forrest Swan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.